FDA ap­proves X4 Phar­ma­ceu­ti­cal­s' pill for ul­tra-rare im­mun­od­e­fi­cien­cy dis­ease

X4 Phar­ma­ceu­ti­cals an­nounced Mon­day morn­ing that the FDA ap­proved its dai­ly pill for WHIM syn­drome — an ul­tra-rare im­mune dis­ease named af­ter its symp­toms.

The pill, ma­vorix­afor, was ap­proved for pa­tients aged 12 and old­er with WHIM syn­drome. X4 Phar­ma­ceu­ti­cals will mar­ket the drug as Xol­rem­di.

The com­pa­ny priced the med­i­cine at $496,400 per year for pa­tients more than 50 kg (rough­ly 110 pounds) and $372,300 for those 50 kg or less, ac­cord­ing to an SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER